2017 ANNUAL RESULTS - INVESTOR CONFERENCE CALL

Acrux (ASX: ACR) will host an Investor Conference Call to discuss the results for the year ended 30 June 2017. Investors and interested parties are invited to join.

Investor Conference Call details:
Date: Thursday 24 August 2017
Time: 10:00am (Australian Eastern Standard Time)
Conference ID: 59729745

Dial-in Details:
Toll Free Dial-in Details: 1800 123 296
Australia: +61 2 8038 5221
New Zealand 0800 452 782
Singapore 800 616 2288
United States 1855 293 1544
United Kingdom 0808 234 0757

A Q&A session will be held following the Company presentation. Shareholders are encouraged to participate by forwarding questions to investor@acrux.com.au in advance of the Conference Call.

Acrux recommends participants dial in at least 5 minutes prior to commencement of the call. A recording of the call will be made available in the 'Investor Centre' section of the Company website at: http://www.acrux.com.au/.

For further information, contact
Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Acrux
Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising specialty and generic topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Marketed products include Axiron®, Evamist® and Lenzetto®. More recently, in addition to specialty products, Acrux has identified and initiated development of a range of generic products. Acrux is leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring more products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au